We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Guru Sonpavde

Guru Sonpavde MD

Bladder Cancer Director, Dana-Farber Cancer Institute, Boston, MA

Recent Contributions to PracticeUpdate:

  1. Practical Issues With Use of Edrafitinib in Urothelial Carcinoma
  2. ASCO: Outcomes of Patients With Metastatic Urothelial Carcinoma Following Discontinuation of Enfortumab-Vedotin
  3. ASCO: Adjuvant Chemotherapy Plus Novel Therapies for Muscle-Invasive Bladder Cancer
  4. Pattern of Adverse Events With New Immuno-Oncology Agents: Implications for Monitoring
  5. AACR: Combination Checkpoint Inhibitor and Chemotherapy for Advanced Urothelial Carcinoma
  6. Integrating Immuno-Oncology and Targeted Therapy for Bladder Cancer in Practice
  7. FGFR Inhibitors in Bladder Cancer
  8. Erdafitinib in Urothelial Carcinoma
  9. Role of Checkpoint Inhibition for Localized Bladder Cancer
  10. Prognostic Model for Patients With Metastatic Urothelial Cancer Receiving Checkpoint Inhibitors

Most Read This Week

Recently Updated